Evidence map›Paper›PMID 41011170›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Association of Erythrocyte-Related Indices with Immune-Related Adverse Events and Survival of Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.

Zhan Wang, Ting Zou, Chen-Wei Liao, Xiang-Ping Li, Zhao-Qian Liu, Ze-Fu Liu, Juan Chen

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhan WangLung Cancer and Gastrointestinal Unit, Department of Medical Oncology, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410031, China.
Ting ZouDepartment of Pharmacy, National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0009-0002-3300-721X
Chen-Wei LiaoXiangya School of Pharmacy, Central South University, Changsha 410078, China.
Xiang-Ping LiNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Zhao-Qian LiuNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0001-5724-1516
Ze-Fu LiuNational Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China.
Juan ChenDepartment of Pharmacy, National Institution of Drug Clinical Trial, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0003-0926-8372

Funding

Changsha Municipal Natural Science Foundation kq2014208Changsha Municipal Natural Science Foundation kq2208408China Postdoctoral Science Foundation 2023M733973National Natural Science Foundation of China 82173901Natural Science Foundation of Hunan Province 2021JJ40325Natural Science Foundation of Hunan Province 2024JJ8180Natural Science Foundation of Hunan Province 2025JJ80133
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

best responseHCTICIsirAEsMCVOSPFSRBC

Identifiers

PMID41011170
PMCPMC12472678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.